Fanconi anemia (FA) is a clinically and genetically heterogenous disease that is usually diagnosed on the basis of chromosomal instability reflecting the hypersensitivity towards the DNA cross-linking agents diepoxybutane (DEB) andlor mitomycin C. A less well-known cellular feature that characterizes FA patients is an intrinsic cell cycle disturbance consisting of prolonged progression through, and arrest within, the G2 phase compartment of the cell cycle. In a collaborative blind study, we have evaluated 72-hour lymphocyte cultures from 66 patients with clinical suspicion of FA both for DEB sensitivity and cell cycle disturbance. A concordant result was obtained in 63 of 66 cases. Each of the 3 discor-F ANCON1 ANEMIA (FA) is an autosomal recessive disease that is genetically heterogenous. If untreated, the course is fatal because of progressive bone marrow failure. Symptomatic therapy consists of blood cell transfusions and ccprticoids. Curative therapy consists of bone marrow transplantation. Less than 50% of FA patients exhibit a pattern of congenital anomalies suggestive of the correct diagnosis before the onset of aplastic anemia.' Four complementation groups have been described.' The only gene to be cloned to date specifies complementation group C located on chromosome 9q22.3 Although sequence and molecular structure of the FACC gene are known: its function remains to be elucidated. The cellular phenotype of FA consists of chromosomal instability, a cell cycle defect, and increased sensitivity towards certain clastogens as well as Until the DNA sequences of all complementation groups are known, the differential diagnosis of FA depends on the determination of the cellular phenotype.
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When establishing the International Fanconi Anemia Registry (IFAR), Auerbach and Schroeder-Kurth agreed on the use of diepoxybutane (DEB) as the best discriminating agent for the diagnosis of FA.' Because of their increased sensitivity towards DEB, FA cells are by this definition DEB+, whereas cells of non-FA patients are DEB-. Diagnostic problems arise in a distinct subgroup of patients in whom the result of the DEB test shows borderline values. A practical problem with the DEB test is that DEB itself is a powerful carcinogen. Many laboratories therefore use mitomycin C (MMC) as a less-dangerous substance for sensitivity testing. However, results of both agents are not fully concordant? In contrast to the numerous studies on DEB and MMC testing, the diagnostic potential of the defective cell cycle seen in FA cells has not been systematically explored. The present study therefore has been designed as a comparative study in which peripheral blood samples of 66 patients with clinical suspicion of FA were evaluated in parallel for their DEB sensitivity and cell cycle defect. Our study seeks to answer the following questions: (l) Do DEB and cell cycle testing identify the same patients as FA or non-FA? (2) 
MATERIALS AND METHODS
Patients. Peripheral blood samples from patients suffering from hematologic diseases such as anemia, pancytopenia, aplastic anemia, thrombocytopenia, or combinations of these symptoms and from patients who presented with a spectrum of congenital phenotypic anomalies reminiscent of FA were sent to the laboratory at Heidelberg, Germany for DEB testing. With informed consent of the families, an aliquot of the blood sample was transferred in parallel to the laboratory in Wurzburg, Germany for cell cycle studies. After 3 years of blind, parallel testing the laboratories compared their results.
Cytogenetic studies. The buffy coat was suspended in 40 mL of complete Chromosome Medium 1A (Biotest-Institut, Berlin, Germany) of which 3 X 10 mL was incubated as parallel experimental lymphocyte cultures for 72 hours at 37.5"C. One culture remained untreated; one received, after 48 hours, 0.1 &nL MMC (Serva, Heidelberg, Germany); and the third was treated, after 24 hours, with 0.1 pglmL DEB (Aldrich, Steinheim, Germany). Colcemid was added after 70 hours, followed by standard procedures for chromosome preparation and staining with Giemsa solution. One hundred metaphases were evaluated from each culture, but not all cultures yielded scorable metaphases. To be included in the study, a cytogenetic result had to be available at least for the DEB-treated culture. Structural chromosome aberrations were specified as follows: percentage of aberrant metaphases; breaks per cell; aberrations per aberrant cell; and types of aberrations. The cut-off values for the discrimination between FA and non-FA patients were as described previously.' Flow cytometric studies. For cell cycle analysis by means of 5-bromo-2'-deoxyuridine (BrdU)/Hoechst 33258-ethidium bromide (EB) flow cytometry, mononuclear blood cells were isolated from 
, and I X 10" mol/L BrdU (Sigma). Cells were stimulated using 1.8 pglmL phytohemagglutinin (Wellcome Diagnostics, Burgwedel. Germany) and incubated at 37.5"C in 5% COz incubators using atmospheric oxygen conditions. After 72 hours, the samples were centrifuged and resuspended in freezing medium containing RPMl 1640. 10% fetal calf serum, and 10% dimethyl sulphoxide and stored frozen at -20°C until analysis. Before bivariate flow cytometric measurements. the frozen aliquots were thawed, pelleted, and resuspended at 4 X IO5 cellslmL in staining buffer containing 0. I mol/L Tris-HCI. cycle distribution of lectin-activated mononuclear blood cells from a 6-year-old healthy donor. Most of his cells have progressed into the second and third cell cycle. There are very few cells left in the G2 phase compartment of the first cell cycle. In contrast, the 72-hour cell cycle distribution of a 5-year-old DEB' patient with the clinical diagnosis of FA (Fig IB) exhibits striking accumulations of cells in the G2 phase compartments of the first and second cell cycle (arrowheads). Exposure to MMC or DEB accentuates these accumulations in FA cultures, but, in addition, causes other cell cycle changes that are not found in untreated cultures such as used for this study (data not shown). The quantitative evaluation of these cytograms (shown in the bottom panels of Fig 1) uses electronic framing of the respective cell cycles and computerized cell cycle fitting as described by Rabinovitch et al."' An important prerequisite for the applicability of the BrdU-Hoechst technique in the human peripheral blood cell system is that incorporation of the base analogue does not by itself cause a cell cycle disturbance. This fact has been established in previous studies with healthy blood donors of various ages." Seventy-two-hour lymphocyte cultures were treated after 24 hours with 0.1 pg/mL DEB. Standard chromosome preparations were scored for structural chromosome aberrations. The results are ranges of values. Not all patient cultures yielded scorable metaphases in the last two categories.
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Cytogenetic testing.
Abbreviations: DEB-, lack of DEB sensitivity; DEB+. DEB sensitive; DEB*, borderline sensitive; MMC, MMC-induced breakage; Spont, spontaneous chromosome breakage.
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Results of spontaneous and MMC-induced breakage are given in 6). was less than 0.28 breakdcell, and there were no cells with more than 1.7 breaks. This group will be referred to as DEB-. The cells of 19 patients proved sensitive towards DEB, as evidenced by their elevated chromosomal breakage rates. In these DEB-sensitive patients, an average of 88.6% aberrant cells and an average of more than 5.63 breakskell were found, including single metaphases with more than 10 breaks. This group will be referred to as DEB+ ( Table 1) . The cytogenetic classification of 5 of the 66 patients proved difficult. These patients were classified as FA-like, because their cells showed a significant increase of chromosomal instability after exposure to DEB. However, their values remained well below the level of 80% to 100% aberrant cells typically found in FA cultures. Moreover, not a single cell with more than 10 aberrations was found in this group. These patients will be referred to as DEB'. More details on these patients will be given in Table 4 (see below). A cytogenetic result was not obtained in all untreated (spontaneous) or MMC-treated cultures. However, the data in Table 1 show that DEB+ cases did not overlap with DEB-cases in their percentages of aberrant cells after MMC exposure. This finding also held for the category breaks per cell, but was not true for the untreated cultures. The evaluation of spontaneous breakage obviously does in no way suffice for the distinction between FA and non-FA patients.
Cell cycle testing.
The results of cell cycle testing are summarized in Table 2 . The cell cycle distributions of patients and controls are presented as cumulative proportions of cells within each of three cell cycle compartments (GI, S, and G2) of four consecutive cell cycles. Because the fraction of noncycling cells (GO) varies greatly among individuals (eg, as a function of donor age), cumulative cell cycle distributions were calculated relative to the growth fraction. The growth fraction (GF) was defined as the sum of all proliferating cells except the nonproliferating GO phase
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PhasedGF PhasedGF cells. Table 2 shows that the cell cycle parameters of 43 of the 66 patients did not deviate significantly from those of 30 healthy controls. Specifically, there was no evidence for G2 phase blockage (sum of G2 phases/GF). This group of patients will be referred to as G2-. The lymphocyte cultures of each of the remaining 23 patients showed a marked shift of their cell cycle distributions. In addition to deviations affecting the G1-and S-phase compartments, there were highly significant accumulations of cells in the G2-phase compartments. Such G2-phase accumulations were described previously for patients with Fanconi
The group of 23 patients exhibiting a disturbed cell cycle distribution will be denoted as G2+.
Correlation between DEB and cell cycle testing. Because the primary emphasis of this study was on the comparison between DEB and cell cycle testing, only those results are shown in Table 3 . DEB-patients were, as a rule, G2-(1 exception), whereas DEB+ patients were G2+ (2 exceptions). All 5 DEB' cases showed G2-phase blockage. In the DEB+ group, the degree of DEB sensitivity (expressed as breaks per cell) was weakly correlated to the extent of G2 phase blockage ( r = .36). However, this weak correlation was caused by a single patient whose lymphocytes were both highly DEB sensitive and G2 arrested. When this patient's data were omitted from the regression analysis, chromosome breakage rates and the extent of G2-phase blockage were unrelated ( r = M).
Exceptional cases. Table 4 lists clinical, cytogenetic, and flow cytometric details of exceptional cases. None of these patients displayed radial ray defects, hyperpigmentation, or other dysmorphic features, except microcephaly (patients no. l and 2). The group of DEB' (borderline-positive) patients consisted of 2 patients with the clinical diagnosis Detailed clinical, cytogenetic and flow cytometric data from the exceptional cases found in this study. of anemia and thrombocytopenia (patients no. 2 and 3) and 3 patients with the diagnosis of incipient aplastic anemia (patients no. 1,4, and 5). In contrast to their borderline DEB and MMC sensitivities on repeated testing, each of these patients displayed unequivocal evidence for GZphase blockage. Table 4 also includes data on the 3 patients in this study in whom DEB and cell cycle testing were clearly discordant (see Table 3 ). The clinical parameter common to these three discordant individuals (patients no. 6 through 8) was the presence of hematoproliferative disease, although the presence of acute lymphoblastic leukemia (ALL) is not typical for FA.'4 Whereas patients no. 6 and 7 experienced a rapid progression of their disease precluding any further cytogenetic or cell genetic testing, patient no. 8 is alive and well after a successful bone marrow transplant.
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DISCUSSION
There is an impressive body of evidence that substantiates the validity of the DEB test for the diagnosis of Fanconi anernia.I5 Indeed, the DEB test undoubtedly represents the gold standard against which any new test must be measured. Despite this excellent record, the DEB test is not trivial because it requires a high degree of cytogenetic expertise and meticulous attention to cell culture and safety conditions. These limitations have motivated several groups to look for alternatives to cytogenetic testing. One such alternative is the cell cycle test, which is based on the observation that FA cells experience difficulties in traversing the S and G2 compartments of the cell cycle.6~"~'6 A number of reports describe the diagnostic potential of the cell cycle test for Fanconi anemia, 13.17-20 but this is the first study that blindly compares cell cycle and DEB testing.
Our A similar high degree of concordance between cell cycle and cytogenetic results was reported by Berger et al, 2o who used nitrogen mustard in both cytogenetic and cell cycle testing. More importantly, these investigators also failed to obtain concordance in 3 patients with myelodysplasia or overt leukemia. The presence of hematoproliferative disease therefore imposes a definitive limitation on the cell cycle test.
Given the likely extent of genetic heterogeneity in FA, the high rate of concordance between DEB+ and G2+-positive cases is rather impressive. In our cohort of 66 patients, the DEB test proved more sensitive than the cell cycle assay with regard to uncovering possible genetic heterogeneity, because 5 of the 24 DEB-positive patients showed unusually low levels of DEB sensitivity. These patients may represent a special complementation group or a subgroup denoting an FA-like entity. The course of their disease differs somewhat from classical FA in that their hematologic symptoms were less severe and progressed very slowly, if at all. Because a G2-phase cell cycle disturbance was observed in all of these patients, DEB testing seems to single out subgroups of patients with atypical FA or FA-like disease that would have been missed by the cell cycle studies alone. On the other hand, the cell cycle disturbance may precede the onset of severe aplastic anemia, as has been observed previously in a 2-year-old child."
In summary, our study confirms that both analytical methods can reliably differentiate between FA and non-FA cells. Cultured lymphocytes with elevated sensitivity towards DEB will display a G2-phase cell cycle defect and vice versa. However, this holds only for nonleukemic cells. Despite this limitation, we still consider the cell cycle test a valuable adjunct to the differential diagnosis of childhood anemias. Owing to its speed and simplicity, the cell cycle test permits a far more liberal screening of patients with any type of dysmorphia or hematologic disturbance that could herald Fanconi anemia. In particular, the many patients carrying the clinical diagnosis of aplastic anemia could be prescreened by cell cycle testing. Confirmatory DEB studies would be required only in cases with evidence for G2-phase arrest. Used in such a sequence, cell cycle and DEB testing offer a fast and economical approach towards the definitive diagnosis of a disease whose clinical presentation is quite variable.' The unambiguous classification at the level of the cellular phenotype provides the only solid basis for current efforts to identify complementation groups and to characterize their underlying genetic defect(s) at the molecular level.
